Innovation in Oncology and Cancer Immunology Research

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

Clinical research has shown that the current wave of checkpoint-centric therapies is beneficial in those patients with immunologically active and highly-mutated so-called ‘hot’ tumors. But they have limited efficacy in those tumor types that lack these properties, commonly known as ‘cold’ tumors.

We are developing complementary platforms including T-cell engagers, targeted cytokines, oncolytic viruses, cancer vaccines, which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people. In parallel, within the area of cancer cell-directed treatments, we are investigating the key drivers of cancer, such as p53 and KRAS, and cancer hallmarks in areas of high unmet patient need. Our research teams are exploring the potential synergies created by these two approaches with the aim of maximizing clinical benefit by developing innovative combination therapies and accelerating the delivery of the next generation of cancer treatments.

Illustration of cancer cells on orange background with accompanying text

Our global research department dedicated to Cancer Immunology is headquartered in Ridgefield, CT, USA, to bring our deep scientific capabilities in Oncology together with our global expertise in Immunology, Biotherapeutics and Small Molecule discovery, allowing us to harness the complementary talents of our scientists, to explore new ways of directing the immune system to profoundly affect the course of cancer